Camptosar
(irinotecan hydrochloride)ApprovedSmall molecule
PfizerIrinotecan is a chemotherapy drug used to treat certain types of cancer, particularly colorectal cancer and sometimes lung or ovarian cancer. It works by damaging cancer cells' DNA to stop them from growing and dividing.[2] Camptosar is currently approved and in use across 12 indications[4].[1]
Camptosar is one of 271 small molecule programs targeting Glioma. It is currently in Approved.
12
Indications
323
Total Trials
5
Active Trials
270
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
307 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Camptosar
PfizerApproved
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
Concurrent Lenvatinib
TTrans Tasman Radiation Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer34 trials
Show 31 more trials
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00064181·86 enrolled
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00003260·109 enrolled
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
Completed·—·Phase 2·NCT01205711·111 enrolled
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
Completed·—·Phase 4·NCT00559676·200 enrolled
Colorectal Cancer25 trials
Show 22 more trials
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Unknown status·—·Phase 2·NCT00408551·20 enrolled
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Unknown status·—·Phase 2·NCT00513266·35 enrolled
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
Terminated·—·Phase 1·NCT00296062·12 enrolled
Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Completed·—·Phase 2·NCT00002933·21 enrolled
Patients With Advanced Solid Tumors11 trials
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00002902
Show 8 more trials
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00006465·22 enrolled
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00047242·30 enrolled
Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003710·12 enrolled
Non-Small Cell Lung Cancer8 trials
Show 5 more trials
Small Cell Lung Cancer8 trials
Show 5 more trials
57 more indications
Pancreatic Cancer8 trials
Show 5 more trials
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Terminated·—·Phase 2·NCT01897454·23 enrolled
Glioblastoma Multiforme6 trials
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Completed·—·Phase 2·NCT00039468·26 enrolled
Show 3 more trials
Esophageal Cancer6 trials
Locally Advanced or Metastatic Solid Tumors5 trials
Cancer of the Esophagus4 trials
Neuroblastoma4 trials
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
Completed·—·Phase 1·NCT00509353·26 enrolled
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Completed·—·Phase 1·NCT00093353·30 enrolled
Patients With Solid Tumors4 trials
Show 1 more trial
Malignant Glioma4 trials
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Completed·—·Phase 1·NCT00005951
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Completed·—·Phase 1·NCT00002988·36 enrolled
Show 1 more trial
Refractory Solid Tumors4 trials
Rhabdomyosarcoma4 trials
Breast Cancer4 trials
Intestinal Cancer3 trials
Lymphoma3 trials
Radiation Therapy3 trials
Glioma3 trials
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Completed·—·Phase 1·NCT00003463
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Completed·—·Phase 2·NCT00268359·68 enrolled
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Withdrawn·—·Phase 1·NCT02055196
Advanced Solid Tumors2 trials
Unresectable Solid Tumor2 trials
Gastric Cancer2 trials
Advanced Cancer2 trials
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
Completed·—·Phase 1·NCT00547547·22 enrolled
Stomach Cancer2 trials
Metastatic Solid Tumors2 trials
Stage III Colon Cancer2 trials
Cancer of the Stomach1 trial
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
Unknown status·—·Phase 2·NCT00005607
Metastatic1 trial
Adenocarcinoma1 trial
Biliary Tract Cancer1 trial
Recurrent Cancer1 trial
Colon Cancer1 trial
Gastrointestinal1 trial
Stage IV Rectal Cancer1 trial
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
Unknown status·—·Phase 1·NCT00392470·20 enrolled
Chronic Myelogenous Leukemia1 trial
Brain Metastases From Solid Tumors1 trial
Locally-advanced Rectal Cancer1 trial
Locally Advanced1 trial
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
Unknown status·—·Phase 2·NCT00134095·70 enrolled
Peritoneal Cancer1 trial
Primary Brain Tumor1 trial
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed·—·Phase 1·NCT00003484·21 enrolled
Metastatic Cancer1 trial
Solid Tumor Malignancies1 trial
Recurrent Hepatoblastoma1 trial
Stage II Colon Cancer1 trial
Diarrhea1 trial
HER2-Positive Solid Tumor1 trial
Soft Tissue Sarcoma1 trial
Glioblastoma1 trial
Radiosurgery Plus Bevacizumab in Glioblastoma
Terminated·—·Phase 1·NCT01086345·9 enrolled
First Line Therapy1 trial
Penile Cancer1 trial
Cancer of the Pancreas1 trial
Advanced Malignancies1 trial
Pancreatic Adenocarcinoma1 trial
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Terminated·—·Phase 2·NCT02345460·1 enrolled
Locally Advanced Cancer1 trial
Colorectal Carcinoma1 trial
Regulatory
FDA Approval Timeline[5]
Jun 14, 1996
CAMPTOSAR
NDA NDA020571
Oct 22, 2015
ONIVYDE
NDA NDA207793
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Camptosar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for irinotecan hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]